-
公开(公告)号：US11905253B2
公开(公告)日：2024-02-20
申请号：US17049680
申请日：2019-04-19
Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITE DE RENNES 1 , CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX , INSTITUT BERGONIE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITE DE BORDEAUX
Inventor： Pierre Vacher , Patrick Legembre , Mickael Jean , Patrick Blanco , Pierre Van De Weghe
IPC: C07D233/64 , A61P37/00 , A61K45/06
CPC classification number: C07D233/64 , A61K45/06 , A61P37/00
Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLCγ1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to compounds of formula (A) as defined in the present text, to a pharmaceutical composition comprising said compounds in a pharmaceutically acceptable medium and to the use of these compounds and compositions as medicament, in particular for their use in the reduction or treatment of the above-mentioned pathologies, and in particular in the treatment of cancers and autoimmune inflammatory disease such as systemic lupus erythematosus, inflammatory condition and Th17-mediated disease.
-
公开(公告)号：US11904268B2
公开(公告)日：2024-02-20
申请号：US18067120
申请日：2022-12-16
Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—
Inventor： Thu-Hoa Tran-Thi , Ana Borta , Mickael Gineys , Marie-Pierre Som , Frédéric Hammel
CPC classification number: B01D53/02 , B01J20/20 , B01D2253/106 , B01D2253/306 , B01D2253/308 , B01D2258/06 , B01J20/103 , B01J20/22 , B01J20/28057
Abstract: A method for preparing a nanoporous silica sol-gel matrix containing at least one amine reactant selected from hydroxylamine, methylhydroxylamine, tertbutylhydroxylamine, methoxyamine, tetraethylenepentamine, dicarboxylic acid dihydrazides, particularly adipic acid dihydrazide, and the salts thereof, said method including the following steps: a) synthesising a gel from tetramethoxysilane or from a mixture of tetramethoxysilane and another organosilicon precursor selected from among phenyltrimethoxysilane, phenyltriethoxysilane, a fluoroalkyltrimethoxysilane, a fluoroalkyltriethoxysilane, a chloroalkylmethoxysilane, a chloroalkylethoxysilane, an alkyltrimethoxysilane, an alkyltriethoxysilane, an aminopropyltriethoxysilane and the mixtures thereof, the synthesis being performed in an aqueous medium at a temperature ranging from 10 to 70° C. in the presence of at least one amine reactant selected from among hydroxylamine, methylhydroxylamine, tertbutylhydroxylamine, methoxyamine, dicarboxylic acid dihydrazides, particularly adipic acid dihydrazide, and the salts thereof; b) drying the gel obtained during step a) so as to obtain a sol-gel matrix containing at least one amine reactant.
-
33.发明公开公开(公告)号：US20240032889A1
公开(公告)日：2024-02-01
申请号：US17631929
申请日：2020-07-31
Applicant: SUPERSONIC IMAGINE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS , Ecole Supérieure de Physique et de Chimie Industrielles de la Ville de Paris
Inventor： William LAMBERT , Alexandre AUBRY , Mathias FINK , Laura COBUS
CPC classification number: A61B8/0833 , A61B8/5207 , A61B8/4488
Abstract: Method for non-invasively characterizing a heterogeneous medium using ultrasound, comprising a step of generating a series of incident ultrasonic waves, a step of recording an experimental reflection matrix Rui(t) defined between the input emission basis (i) and an output reception basis (u), a step of determining a response REP(r, Δr) of the medium between an input virtual transducer (TVin) calculated based on an input focusing of the experimental reflection matrix that creates an input focal spot around a first point (P1), and an output virtual transducer (TVout) calculated based on an output focusing of the experimental reflection matrix that creates an output focal spot around a second point (P2), said response being expressed as a function of a central point (PC) of spatial position (r) in the medium located midway between the first and second points (P1, P2).
-
公开(公告)号：US20240018715A1
公开(公告)日：2024-01-18
申请号：US18032044
申请日：2021-10-15
Applicant: Centre National de la Recherche Scientifique (CNRS) , Universite Jean Monnet Saint Etienne , La Tannerie Vegetale , Université Claude Bernard Lyon 1
Inventor： Fanny DELEAGE , Yvan CHALAMET
CPC classification number: D06N3/0061 , C14C3/26
Abstract: The present disclosure relates to a method for the preparation, from a mixture comprising (i) plant proteins, (ii) one or more plant tanning agents, (iii) one or more plasticizers, of a biobased material that may resemble animal leather.
-
35.发明公开公开(公告)号：US20240011940A1
公开(公告)日：2024-01-11
申请号：US18254881
申请日：2021-12-03
Inventor： Guilhem LARRIEU
IPC: G01N27/414
CPC classification number: G01N27/4146 , G01N27/4148
Abstract: The invention relates to a method for manufacturing a platform for cellular interfacing, the platform being manufactured over a predetermined bulk substrate, the method being a top-down method.
According to the invention, such a method comprises the following steps in order:
creating (E10) vertical nanowires over the bulk substrate;
depositing (E30) a Si layer
creating (E40) the access lines for accessing the nanowires;
selective silicidation (E50) of the access lines and of the nanowires;
metal structuring (E60) of the access lines;
depositing (E60) an insulating layer for liquid measurement;
selective removal (E70) of the insulating layer on the nanoprobes.-
Patent Agency Ranking
公开(公告)号：US20240006082A1
公开(公告)日：2024-01-04
申请号：US18252831
申请日：2021-11-16
Applicant: HOSPICES CIVILS DE LYON , UNIVERSITE CLAUDE BERNARD LYON 1 , ECOLE NORMALE SUPERIEURE DE LYON , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , INSERM (Institut National de la Sante et de la Recherche Medicale)
Inventor： Jean-Philippe RASIGADE
Abstract: The present invention relates to a method for detecting an infectious transmission in a population, the method being characterised in that it comprises implementing, by data processing means (20) of a client (2), steps of: (b) for a plurality of infectious agent isolates, each associated with an individual of said population, obtaining a vector with values descriptive of the isolate; (c) for each pair of a first isolate (X) and a second isolate (Y) of the plurality, respectively associated with a first individual and a second individual of said population: (c1) calculating a first number of isolates (n(X)) corresponding to the number of isolates of said plurality having a distance to the first isolate (X) less than or equal to a reference distance between the first and second isolates (X, Y), and a second number of isolates (n(Y)) corresponding to the number of isolates of said plurality having a distance to the second isolate (Y) less than or equal to said reference distance between the first and second isolates (X, Y), each distance between two isolates being representative of a dissimilarity between the vectors of values descriptive of these two isolates; (c2) estimating a probability (TXY) of direct infectious transmission between the first and second individuals as a function of said first and second number of isolates (n(X), n(Y)); (d) detecting or not detecting an infectious transmission in said population as a function of the estimated probabilities (TXY) of direct infectious transition between each pair of individuals.
-
公开(公告)号：US20240000833A1
公开(公告)日：2024-01-04
申请号：US18309047
申请日：2023-04-28
Applicant: Institut National de la Santé et de la Recherche Médicale , Universite d'Aix Marseille , Centre National de la Recherche Scientifique (CNRS) , Max Delbruck Center for Molecular Medicine (MDC)
Inventor： Michael SIEWEKE , Kaaweh MOLAWI , Laufey GEIRSDOTTIR
CPC classification number: A61K35/15 , C12N5/0645 , A61P31/12 , A61P31/04 , A61P31/10 , A61P35/00 , C12N2501/22
Abstract: The present invention relates to methods for expanding a population of alveolar macrophages in a long term culture. In particular, an object of the present invention relates to a method of expanding a population of alveolar macrophages in a long term culture comprising culturing the population of alveolar macrophages in a culture medium supplemented with an amount of GM-CSF.
-
公开(公告)号：US11857604B2
公开(公告)日：2024-01-02
申请号：US16755866
申请日：2018-10-12
Applicant: NH THERAGUIX , Universite Claude Bernard Lyon 1 , Centre National de La Recherche Scientifique—CNRS—
Inventor： Olivier Tillement , François Lux , Fabien Rossetti , Vu-Long Tran , Clélia Mathieu , Myleva Dahan
IPC: A61K38/31 , A61K47/69 , A61P35/00 , A61K33/243 , A61K9/14 , A61K31/704 , A61K49/00 , A61K49/12 , A61K49/18 , B82Y5/00 , A61K33/244 , A61K9/00
CPC classification number: A61K38/31 , A61K9/146 , A61K31/704 , A61K33/243 , A61K33/244 , A61K47/6929 , A61K49/0002 , A61K49/128 , A61K49/1881 , A61P35/00 , B82Y5/00 , A61K9/0019
Abstract: The present invention relates to the field of nanovectors for the delivery of active substances in the body, in particular for the treatment of tumours. In particular, the use of these nanovectors makes it possible to improve the pharmacokinetics of the active substances with a more selective delivery, for example in the tumour tissues.
-
39.发明公开公开(公告)号：US20230416398A1
公开(公告)日：2023-12-28
申请号：US18321094
申请日：2023-05-22
Applicant: OGD2 PHARMA , NANTES UNIVERSITÉ , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , INSTITUT DE CANCEROLOGIE DE L'OUEST
Inventor： Stéphane BIRKLE , Julien FLEURENCE , Sébastien FARAJ , Jean-Marc LE DOUSSAL , Denis COCHONNEAU , Mickaël TERME , Brigitte ASSOULINE
IPC: C07K16/30
CPC classification number: C07K16/3084 , C07K2317/24 , C07K2317/565 , C07K2317/622
Abstract: Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.
-
公开(公告)号：US20230383350A1
公开(公告)日：2023-11-30
申请号：US18249756
申请日：2021-10-19
Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITE PAUL SABATGIER TOULOUSE III
Inventor： Jean-luc DAVIGNON , Yannick DEGBOE , Katy DIALLO , Arnaud CONSTANTIN , Benjamin RAUWEL , Jean-Frederic BOYER , Michel BARON
IPC: C12Q1/6883 , C07K16/24 , A61K38/17 , A61P19/02
CPC classification number: C12Q1/6883 , C07K16/241 , A61K38/1793 , A61P19/02 , C12Q2600/158 , C12Q2600/106
Abstract: Rheumatoid arthritis (RA) is the most prevalent chronic autoimmune inflammatory rheumatism. Its pathophysiology is largely dependent on TNF. Severe RA as well as several other inflammatory and autoimmune diseases are treated with TNF inhibitors (TNFi). However, to date only 30-50% achieve low disease activity or remission with this treatment regimen and some patients experience secondary non-response or relapse. Herein, the inventors evaluated by RT-qPCR the mRNA expression of CD36, which was already described to be regulated by TNFi5, some specific NRF2 target genes (FBX030, GABARA, LBR, MAFG, OSGIN1, HMOX1), which play a role in the anti-oxidative stress response or anti-inflammatory pathway, and the expression of CSMD1, an anti-inflammatory gene that we observed as up-regulated by all TNFi. Interestingly, they observed 2 different subsets of healthy donors: (i) donors in which TNFi stimulation increased mRNA of target genes in macrophages and (ii) conversely donors with no significant upregulation in transcription of these target genes. Then they classified donors two different status, “activators” or “non-activators” of tmTNF reverse signaling after TNFi stimulation, which correlates to clinically responder and non-responders to TNFi. Thus, based on all these observations, they developed an in vitro method for predicting the response to TNF inhibitors in patient in need thereof.
-
-
-
-
-
-
-
-
-
Search Results
2053
records
(took 0.034 seconds)
